TWICE DAILY ADMINISTRATION OF TENOFOVIR ...TWICE DAILY ADMINISTRATION OF TENOFOVIR ALAFENAMIDE IN...
Transcript of TWICE DAILY ADMINISTRATION OF TENOFOVIR ...TWICE DAILY ADMINISTRATION OF TENOFOVIR ALAFENAMIDE IN...
TWICE DAILY ADMINISTRATION OF TENOFOVIR ALAFENAMIDE IN COMBINATION WITH RIFAMPIN:
POTENTIAL FOR TENOFOVIR ALAFENAMIDE USE IN HIV-TB COINFECTION
J.M. Custodio, S. West, J. Lutz, A. Vu, D. Xiao, S. Collins, M. Das, B.P. Kearney, A. Mathias
Abstract PS13/4
TWICE DAILY ADMINISTRATION OF TENOFOVIR ALAFENAMIDE IN COMBINATION WITH RIFAMPIN: POTENTIAL FOR TENOFOVIR ALAFENAMIDE USE IN HIV-TB COINFECTION
TAF is a substrate of human drug transportersRIF is commonly used in a multi-drug regimen for TBRIF is potent inducer and associated with DDI
DDI Mechanism TAF RIF
Drug transportersP-gp/BCRP Substrate Inducer
OATP1B1/1B3 Substrate Inducer
To evaluate the PK of TAF, TFV-DP, and plasma TFV, following co-administration of TAF BID with RIF 600 mg OD vs TAF OD
Custodio K, et al; 16th EACS, Milan, Italy, October 25-27, 2017; Abst. PS13/4.
STUDY DESIGN
Phase 1, open-label, parallel-design, multiple-dose, single center study in healthy subjects
3
TAF QD administered as Bictegravir/Emtricitabine/TAF QD; TAF BID administered as Bictegravir/Emtricitabine/TAF BID
Custodio K, et al; 16th EACS, Milan, Italy, October 25-27, 2017; Abst. PS13/4.
TAF 25 mg QD Cohort 1n=26
Intensive plasma PK sampling
Day1
Day28
Cohort 2n=26
600 mg RIF
TAF 25 mg BID600 mg RIF
Discharge
Intensive plasma PK sampling
Day1
Day28
Day35
RESULTS: TAF PLASMA PK = 15% REDUCTION
Custodio K, et al; 16th EACS, Milan, Italy, October 25-27, 2017; Abst. PS13/4.
TAF PK Mean (%CV)
TAF QD n=26 (ref)
TAF BID + RIFn=26 (test)
GLSM Ratio 90% CI
AUC0-24 (ng•h/mL) 345 (52) 290 (48) 85.8 (69.7, 106)
Cmax (ng/mL) 471 (72) 207 (64) 44.1 (33.2, 58.7)
0 4 8 12 16 20 24
Mea
n (S
D) T
AFC
onc
(ng/
mL)
Time (h)
TAF BID + RIFTAF QD
1000
100
10
1
0.1
0.01
RESULTS: PLASMA TFV PK = 30% REDUCTION
Custodio K, et al; 16th EACS, Milan, Italy, October 25-27, 2017; Abst. PS13/4.
TAF PK Mean (%CV)
TAF QD n=26 (ref)
TAF BID + RIFn=26 (test)
GLSM Ratio 90% CI
AUC0-24 (ng•h/mL) 348 (20) 277 (19) 79.9 (73.1, 87.3)
0 4 8 12 16 20 24
Mea
n (S
D) T
FVC
onc
(ng/
mL)
Time (h)
TAF BID + RIFTAF QD
100
10
1
RESULTS: TFV-DP PK = 24% REDUCTION
Custodio K, et al; 16th EACS, Milan, Italy, October 25-27, 2017; Abst. PS13/4.
TFV-DP PK GLSM Ratio (90% CI)
AUC0-24 (fmol•h/106 cells) 76.3 (58.7, 99.2)
Conclusions: TAF plus RIF was well toleratedNo Grade 3 / 4 AEs or lab changesPD evaluations in patients with TB and HIV needed
Historical Steady-State TFV-DP datawith TDF 300 mg: 85-222 fmol/106 cells1-3
0 4 8 12 16 20 24
Mea
n (9
5% C
I) TF
V-D
P (fm
ol/1
06ce
lls
Time (h)
TAF BID + RIFTAF QD1000
10
1
10
100
1